Valemetostat Tosylate (DS-3201b), an Enhancer of Zeste Homolog (EZH) 1/2 Dual Inhibitor, for Relapsed/Refractory Peripheral T-Cell Lymphoma (VALENTINE-PTCL01)
A phase 2 trial of Valemetostat Tosylate in peripheral T-cell lymphomas and non-Hodgkin lymphoma, run by Daiichi Sankyo, active and no longer recruiting.
Overview
Valemetostat Tosylate (DS-3201b), an Enhancer of Zeste Homolog (EZH) 1/2 Dual Inhibitor, for Relapsed/Refractory Peripheral T-Cell Lymphoma (VALENTINE-PTCL01) is a phase 2 interventional study registered as NCT04703192 by Daiichi Sankyo, with 155 participants enrolled, started 2021-06-03 and due to reach its primary completion in 2023-05-10. Interventions recorded: Valemetostat Tosylate. Results have been posted on the registry.
Similar pages
not linked directly; found by shared links- TrialA First-in-Human Trial of DS3790a in Participants With Hematological Malignancies
Shares Daiichi Sankyo, Non-Hodgkin lymphoma (all types) and the tag pipeline.
- TrialA Study of GNC-038 Injection in Patients With Relapsed or Refractory NK/ T-cell Lymphoma, AITL, and Other NHL
Shares Peripheral T-cell lymphomas (including cutaneous T-cell lymphoma), Non-Hodgkin lymphoma (all types) and the tag pipeline.
- TrialAdaptive Dual-Target CAR-T Cells for Relapsed or Refractory Hematologic Malignancies
Shares Peripheral T-cell lymphomas (including cutaneous T-cell lymphoma), Non-Hodgkin lymphoma (all types) and the tag pipeline.
- TrialA Study of GFH009 Monotherapy in Patients with Relapsed or Refractory Peripheral T-cell Lymphoma (PTCL)
Shares Peripheral T-cell lymphomas (including cutaneous T-cell lymphoma) and the tag pipeline.
- TrialEvaluate the Safety and Clinical Activity of HH2853
Shares Peripheral T-cell lymphomas (including cutaneous T-cell lymphoma), Non-Hodgkin lymphoma (all types) and the tag pipeline.
- TrialPhase II Clinical Trial of CNCT19 Cell Injection in the Treatment of Relapsed or Refractory Non-Hodgkin's Lymphoma
Shares Non-Hodgkin lymphoma (all types) and the tag pipeline.
- TrialClinical Study of U16 in Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma
Shares Non-Hodgkin lymphoma (all types) and the tag pipeline.
- TrialA Study Evaluating the Safety and Efficacy of BEAM-201 in Relapsed/Refractory T-Cell Acute Lymphoblastic Leukemia (T-ALL) or T-Cell Lymphoblastic Lymphoma (T-LL)
Shares Non-Hodgkin lymphoma (all types) and the tag pipeline.